<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1624">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140018</url>
  </required_header>
  <id_info>
    <org_study_id>PROCARE2</org_study_id>
    <nct_id>NCT05140018</nct_id>
  </id_info>
  <brief_title>Incidence, Course and Outcome of ABMR in Kidney Transplantation</brief_title>
  <acronym>PROCARE2</acronym>
  <official_title>Incidence, Course and Outcome of Cellular and Antibody-mediated Rejection in Immunological High-risk Kidney Transplantation, a Prospective Cohort PROCARE2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dutch Kidney Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Despite improved patient and graft survival in renal transplant recipients, still&#xD;
      20% of the patients reaches end-stage renal disease within 5 years after transplantation.&#xD;
      Antibody-mediated rejection (ABMR) is one of the major causes of early graft loss and perhaps&#xD;
      even more important of late deterioration of graft function&#xD;
&#xD;
      Objective: Evaluate the occurrence of antibody mediated rejection (ABMR) and mixed ABMR and&#xD;
      cellular/ T-cell mediated rejection (TCMR), in patients treated with the currently prevailing&#xD;
      immunosuppressive regimens, and relate them to outcome (graft survival, function,&#xD;
      proteinuria, histology)&#xD;
&#xD;
      Study design: Clinical cohort study.&#xD;
&#xD;
      Study population: patients of &gt;18 years old, about to receive a post mortal of living donor&#xD;
      renal transplant with an immunological high risk for ABMR.&#xD;
&#xD;
      Main study parameters/endpoints: main study endpoints are the occurrence of ABMR, mixed&#xD;
      ABMR/TCMR and renal function after 1 year of follow-up.&#xD;
&#xD;
      The main study parameter will be mapping the immune system, including B-cells, (non-)HLA&#xD;
      antibodies, interaction between B-cells and T follicular helper cells, and complete immune&#xD;
      profiling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Antibody-Mediated Rejection (ABMR)</measure>
    <time_frame>within 12 months after transplantation</time_frame>
    <description>Incidence of Antibody-Mediated Rejection (ABMR) as histopathological diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of mixed Antibody-Mediated Rejection / T-Cell Mediated Rejection (ABMR/TCMR)</measure>
    <time_frame>within 12 months after transplantation</time_frame>
    <description>Incidence of mixed Antibody-Mediated Rejection / T-Cell Mediated Rejection as histopathological diagnosis(ABMR/TCMR) as histopathological diagnosis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Kidney transplant function</measure>
    <time_frame>at 12 months after transplantation</time_frame>
    <description>as measured by eGFR and proteinuria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of Human-Leukocyte Antigen (HLA) antibodies</measure>
    <time_frame>At 3 and 12 months after transplantation</time_frame>
    <description>As measured by Luminex assay at 3 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of non-HLA antibodies</measure>
    <time_frame>At 3 and 12 months after transplantation</time_frame>
    <description>Development of non-HLA antibodies as measured by a cell-based endothelial assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney transplant survival</measure>
    <time_frame>At 12 months after transplantation</time_frame>
    <description>Kidney transplant survival in patients experiencing ABMR versus those not experiencing ABMR</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Antibody-mediated Rejection</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Kidney Transplant Recipients with an immunological high risk for ABMR</arm_group_label>
    <description>Kidney transplant recipients ≥18 years old&#xD;
About to receive a post mortal or living donor renal transplant&#xD;
Immunological high risk for rejection&#xD;
Luminex positive DSAs ; or&#xD;
Retransplantation with repeated mismatch ; or&#xD;
Husband to wife donation (after fathering children); or&#xD;
Offspring to mother donation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Living Kidney Donors</arm_group_label>
    <description>Participants who are about to donate their kidney to a Recipient with a high immunological risk (as described above)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Kidney Transplantation</intervention_name>
    <description>All participants will receive a kidney transplantation from a living donor or deceased donor</description>
    <arm_group_label>Kidney Transplant Recipients with an immunological high risk for ABMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Immunosuppression</intervention_name>
    <description>All participants will receive immunosuppresive drugs to prevent rejection of de kidney transplant graft.</description>
    <arm_group_label>Kidney Transplant Recipients with an immunological high risk for ABMR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nephrectomy (kidney donation)</intervention_name>
    <description>All kidney donors will receive a nephrectomy for kidney donation</description>
    <arm_group_label>Living Kidney Donors</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral Blood Mononuclear Cells (PBMCs) Kidney biopsy material (in case when kidney biopsy&#xD;
      is performed in the follow-up) Iliac lymph nodes from 15 selected kidney transplant&#xD;
      recipients&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with eind-stage renale disease (ESRD) who are about to receive a kidney transplant&#xD;
        from a living or deceased donor, with an elevated immunological risk (higher risk for&#xD;
        (antibody-mediated) rejection).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Kidney transplant recipients ≥18 years old&#xD;
&#xD;
          -  About to receive a post mortal or living donor renal transplant&#xD;
&#xD;
          -  written informed consent (is able to read of understand in Dutch)&#xD;
&#xD;
          -  Immunological high risk for rejection&#xD;
&#xD;
               1. Luminex positive DSAs ; or&#xD;
&#xD;
               2. Retransplantation with repeated mismatch ; or&#xD;
&#xD;
               3. Husband to wife donation (after fathering children); or&#xD;
&#xD;
               4. Offspring to mother donation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No immunological high risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hendrikus Otten, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan-Stephan Sanders, MD PhD</last_name>
    <phone>+31503612955</phone>
    <email>j.sanders@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joost van den Born, MD PhD</last_name>
    <phone>+31503612955</phone>
    <email>j.c.van.den.born@umcg.nl</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 17, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>J.S.F. Sanders</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

